QuantiBact is developing a technology that will significantly improve molecular diagnostics in the near future.

QuantiBact is a biotech company founded on research of nucleic acid analogues performed at The University of Southern Denmark and Hvidovre Hospital.

We are developing diagnostic tools for the detection of infectious diseases by: increasing specificity, minimizing turn-around time and increasing fidelity of quantification. Our technology will significantly improve hybridization and PCR based assays.

http://quantibact.com/